Circulating levels of a soluble form of receptor for advanced glycation end products and high-mobility group box chromosomal protein 1 in patients with acute pancreatitis

Pancreas

Volumn 38, Issue 8, 2009, Pages

  Lindström, Outi ^a   Tukiainen, Eija ^a   Kylänpää, Leena ^a   Mentula, Panu ^a   Rouhiainen, Ari ^a   Puolakkainen, Pauli ^a,b   Rauvala, Heikki ^a   Repo, Heikki ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Acute pancreatitis; HMGB1; Mortality; Organ failure; SRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CHROMOSOME PROTEIN;

ACUTE PANCREATITIS; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HMGB1 PROTEIN; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; PANCREATITIS; PROGNOSIS; RECEPTORS, IMMUNOLOGIC; RESPIRATION DISORDERS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; YOUNG ADULT;

EID: 70350647307     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181bb59a7     Document Type: Article

References (72)

1. Steinberg W, Tenner S. Acute pancreatitis. N Engl J Med. 1994;330:1198-1210.
2. Bradley EL 3rd. A fifteen year experience with open drainage for infected pancreatic necrosis. Surg Gynecol Obstet. 1993;177:215-222.
3. Neoptolemos JP, Raraty M, Finch M, et al. Acute pancreatitis: the substantial human and financial costs. Gut. 1998;42:886-891.
4. Wilson PG, Manji M, Neoptolemos JP. Acute pancreatitis as a model of sepsis. J Antimicrob Chemother. 1998;41(suppl A):51-63.
5. Ulloa L, Tracey KJ. The Bcytokine profile[: a code for sepsis. Trends Mol Med. 2005;11:56-63.
6. Goodwin GH, Shooter KV, Johns EW. Interaction of a non-histone chromatin protein (high-mobility group protein 2) with DNA. Eur J Biochem. 1975;54:427-433.
7. Melvin VS, Edwards DP. Coregulatory proteins in steroid hormone receptor action: the role of chromatin high mobility group proteins HMG-1 and -2. Steroids. 1999;64:576-586.
8. Bustin M. Regulation of DNA-dependent activities by functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol. 1999;19:5237-5246.
9. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248-251.
10. Wang H, Yang H, Czura CJ, et al. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med. 2001;164:1768-1773.
11. Taniguchi N, Kawahara K, Yone K, et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum. 2003;48:971-981.
12. Ueno H, Matsuda T, Hashimoto S, et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med. 2004;170:1310-1316.
13. Ogawa EN, Ishizaka A, Tasaka S, et al. Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. Am J Respir Crit Care Med. 2006;174:400-407.
14. Tsung A, Sahai R, Tanaka H, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemiaYreperfusion. J Exp Med. 2005;201:1135-1143.
15. Watanabe T, Kubota S, Nagaya M, et al. The role of HMGB-1 on the development of necrosis during hepatic ischemia/reperfusion injury in mice. J Surg Res. 2005;124:59-66.
16. Steer SA, Scarim AL, Chambers KT, et al. Interleukin-1 stimulates beta-cell necrosis and release of the immunological adjuvant HMGB1. PLoS Med. 2006;3:253-266.
17. Zamora R, Grishin A, Wong C, et al. High-mobility group box 1 protein is an inflammatory mediator in necrotizing enterocolitis: protective effect of the macrophage deactivator semapimod. Am J Physiol Gastrointest Liver Physiol. 2005;289:643-652.
18. Ombrellino M, Wang H, Ajemian MS, et al. Increased serum concentrations of high-mobility-group protein 1 in haemorrhagic shock. Lancet. 1999;354:1446-1447.
19. Harris HE, Andersson U. Mini-review: the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol. 2004;34:1503-1512.
20. Chen G, Li J, Ochani M, et al. Bacterial endotoxin stimulates macrophages to release HMGB1 partly through CD14- and TNF-dependent mechanisms. J Leukoc Biol. 2004;76:994-1001.
21. Mullins GE, Sunden-Cullberg J, Johansson A-S, et al. Activation of human umbilical vein endothelial cells leads to relocation and release of high-mobility group box chromosomal protein 1. Scand J Immunol. 2004;60:566-573.
22. Wang H, Yang H, Tracey KJ. Extracellular role of HMGB1 in inflammation and sepsis. J Int Med. 2004;255:320-331.
23. Yang H, Tracey KJ. High mobility group box 1 (HMGB1). Crit Care Med. 2005;33(suppl):472-474.
24. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine & Growth Fact Rev. 2006;17:189-201.
25. Rauvala H, Rouhiainen A. RAGE as a receptor of HMGB1 (amphoterin): roles in health and disease. Curr Mol Med. 2007;7:725-734.
26. Schmidt AM, Hofmann M, Taguchi A, et al. RAGE: a multiligand receptor contributing to the cellular response in diabetic vasculopathy and inflammation. Semin Thromb Hemost. 2000;26:485-493.
27. Park IH, Yeon SI, Youn JH, et al. Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. Mol Immunol. 2004;40:1203-1211.
28. Schmidt A, Yan SD, Yan SF, et al. The biology of the receptor for advanced glycation end products and its ligands. Biochem Biophys Acta. 2000;1498:99-111.
29. Schmidt A, Yan SD, Yan SF, et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest. 2001;108:949-955.
30. Andrassy M, Igwe J, Autschbach F, et al. Posttranslationally modified proteins as mediators of sustained intestinal inflammation. Am J Pathol. 2006;169:1223-1237.
31. Bierhaus A, Humpert P, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med. 2005;83:876-886.
32. Rouhiainen A, Kuja-Panula J, Wilkman E, et al. Regulation of monocyte migration by amphoterin (HMGB1). Blood. 2004; 104:1174-1182.
33. Kokkola R, Andersson Á, Mullins G, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol. 2005;61:1-9.
34. Yu M, Wang H, Ding A, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006;26:174-179.
35. Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variant of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003;370:1097-1109.
36. Hudson BI, Harja E, Moser B, et al. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease, the next C-reactive protein? Arterioscler Thromb Vasc Biol. 2005;25:879-882.
37. Kalousova M, Jachymova M, Mestek O, et al. Receptor for advanced glycation end productsVsoluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant. 2007; 22:2020-2026. (Pubitemid 47244776)
38. Uchida T, Shirasawa M, Ware L, et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med. 2006;173:1008-1015.
39. Pullerits R, Bokarewa M, Dahlberg L, et al. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther. 2005;7:817-824.
40. Emanuele E, D'Angelo A, Tomaino C, et al. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol. 2005;62:1734-1736. (Pubitemid 41626671)
41. Geroldi D, Falcone C, Emanuele E, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertensi. 2005;23:1725-1729. (Pubitemid 41233433)
42. Yasuda T, Ueda T, Takeyama Y, et al. Significant increase of serum high-mobility group box chromosomal protein 1 levels in patients with severe acute pancreatitis. Pancreas. 2006;33:359-363.
43. Bradley EL. A clinically based classification system for acute pancreatitis. Arch Surg. 1993;128:586-590.
44. Parkkinen J, Raulo E, Merenmies J, et al. Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J Biol Chem. 1993;268:19726-19738.
45. Rouhiainen A, Imai S, Rauvala H, et al. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation. Thromb Haemost. 2000;84:1087-1094.
46. Sunden-Cullberg J, Norrby-Teglund A, Treutiger CJ. The role of high mobility group box-1 protein in severe sepsis. Curr Opin Infect Dis. 2006;19:231-236.
47. Johnson CD, Abu-Hilal M. Persistent organ failure during the first week as a marker of fatal outcome in acute pancreatitis. Gut. 2004;53:1340-1344.
48. Mullins G, Sunden-Cullberg J, Tokics L, et al. Increase of Soluble RAGE in Patients With Severe Sepsis/Septic Shock [PhD thesis]. Stockholm, Sweden: Karolinska University, Department of Medicine; 2005.
49. Kraft R, Zedler S, Faist E. Levels of soluble and endogenous secretory RAGE after severe accidental trauma [abstract]. Inflamm Res. 2007;(suppl 2):322-323.
50. Bopp C, Hofer S, Weitz J, et al. sRAGE is elevated in septic patients and associated with patients outcome. J Surg Res. 2008;147:79-83.
51. Basta G, Sironi AM, Lazzerini G, et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab. 2006;91:4628-4634.
52. Santilli F, Bucciarelli L, Noto D, et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med. 2007;43:1255-1262.
53. Falcone C, Emanuele E, D'Angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005;25:1032-1037. (Pubitemid 40627851)
54. Gross S, van Ree RM, Oterdoom LH, et al. Low levels of sRAGE are associated with increased risk for mortality in renal transplant recipients. Transplantation. 2007;84:659-663.
55. Nakamura K, Yamagishi S, Nakamura Y, et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-IIYexposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res. 2005;70:137-141.
56. Nakamura K, Yamagishi S, Adachi H, et al. Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev. 2007;23:368-371. (Pubitemid 47091239)
57. Tan KC, Shiu SW, Chow WS, et al. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia. 2006;49:2756-2762.
58. Romero R, Espinoza J, Hassan S, et al. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory (esRAGE) in amniotic fluid: modulation by infection and inflammation. J Perinat Med. 2008;36:388-398.
59. Raman KG, Sappington PL, Yang R, et al. The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol. 2006;291:556-565.
60. Wear-Maggitti K, Lee J, Conejero A, et al. Use of topical sRAGE in diabetic wounds increases neovascularization and granulation tissue formation. Ann Plast Surg. 2004;52:519-521.
61. Bucciarelli LG, Kaneko M, Ananthakrishnan R, et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation. 2006;113:1226-1234.
62. Forbes JM, Thorpe SR, Thallas-Bonke V, et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol. 2005;16:2363-2372.
63. Sunden-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med. 2005;33:564-573.
64. Ilmakunnas M, Tukiainen EM, Rouhiainen A, et al. High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Transpl. 2008;14:1517-1525.
65. Karlsson S, Pettilä V, Tenhunen J, et al. HMGB1 as a predictor of organ dysfunction and outcome in patients with severe sepsis. Intensive Care Med. 2008;34:1046-1053. (Pubitemid 351903793)
66. Sunden-Cullberg J. On the Role of HMGB1 and Resistin in Severe Sepsis and Septic Shock [academic dissertation]. Stockholm, Sweden: Karolinska Institutet; 2008.
67. Bonaldi T, Talamo F, Scaffidi P, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 2003;22:5551-5560.
68. Youn JH, Shin J-S. Nucleocytoplasmic shuttling of HMGB1 is regulated by phosphorylation that redirects it toward secretion. J Immunol. 2006;177:7889-7897.
69. Lin X, Yang H, Sakuragi T, et al. Alfa-chemokine receptor blockade reduces high mobility group box 1 protein induced lung inflammation and injury and improves survival in sepsis. Am J Physiol Lung Cell Mol Physiol. 2005;289:583-590.
70. Wang H, Liao H, Ochani M, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nature Med. 2004;10:1216-1221.
71. Chen G, Li J, Qiang X, et al. Suppression of HMGB1 release by stearoyl lysophosphatidylcholine: an additional mechanism for its therapeutic effects in experimental sepsis. J Lipid Res. 2005;46:623-627.
72. Sawa H, Ueda T, Takeyama Y, et al. Blockade of high mobility group box-1 protein attenuates experimental severe acute pancreatitis. World J Gastroenterol. 2006;12:7666-7670.